EffRx Pharmaceuticals
EffRx Pharmaceuticals is a Swiss specialty pharmaceutical company commercializing niche and orphan medicines for endocrinology, rare diseases, and musculoskeletal disorders, combining direct Swiss sales with global out-licensing of its lead product, Binosto.
- Company typePrivate
- Founded1998
- HeadquartersFreienbach, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What EffRx Pharmaceuticals does
EffRx Pharmaceuticals SA is a commercial-stage Swiss specialty pharmaceutical company headquartered in Freienbach, Switzerland, focused on the late-stage development and commercialization of prescription medications for niche and orphan indications in endocrinology, rare diseases, and musculoskeletal disorders. The company's product portfolio centers on Binosto, a proprietary buffered effervescent alendronate tablet (the first and only buffered solution for osteoporosis treatment), alongside in-licensed rare disease therapies including Alkindi (pediatric hydrocortisone for adrenal insufficiency), Efmody (modified-release hydrocortisone for congenital adrenal hyperplasia), Miglustat Dipharma (for Gaucher disease and Niemann-Pick type C), and additional Swiss-marketed products (Dibase, Testavan, Lysodren, Metopiron). Binosto is distributed globally through exclusive licensing arrangements with regional partners (Radius Health in the US, Lupin in Vietnam/Philippines, Pyridam Farma in Indonesia, Compai Pharma in Malaysia), and has secured approximately 30 marketing authorizations worldwide.
The company operates a hybrid commercial model: direct sales infrastructure in Switzerland for its full niche portfolio, and out-licensing to specialized partners across international markets, with EffRx retaining product supply responsibilities. EffRx co-founded the World Orphan Drug Alliance (WODA) in May 2022, a distribution alliance covering 68 countries and 64 million potential rare disease patients across Central/Eastern Europe, the Middle East, North Africa, Russia/CIS, and Latin America. In May 2023, EffRx was acquired by Italian specialty pharma company Abiogen Pharma S.p.A., which is the controlling parent and provides strategic depth in osteoarticular and bone metabolism diseases. As of January 2025, EffRx has been awarded the EcoVadis Silver Medal, placing it in the top 15% of companies evaluated for sustainability management.
EffRx Pharmaceuticals firmographics
Firmographics- Name
- EffRx Pharmaceuticals
- Legal name
- EffRx Pharmaceuticals SA
- Website
- https://effrx.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- EffRx Pharmaceuticals is a Swiss specialty pharmaceutical company commercializing niche and orphan medicines for endocrinology, rare diseases, and musculoskeletal disorders, combining direct Swiss sales with global out-licensing of its lead product, Binosto.
- Ownership category
- akta.pro rank
EffRx Pharmaceuticals industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)
- akta.pro secondary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where EffRx Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Freienbach
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
EffRx Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- Product Licensing and Royalty Revenue: EffRx generates revenue through exclusive licensing agreements with regional commercialization partners. The company grants licenses to commercialize Binosto in specific territories while maintaining product supply. Partners pay licensing fees and royalties for the right to commercialize the product.
- Direct Product Sales in Switzerland: EffRx directly commercializes its portfolio of rare disease, endocrinology, and musculoskeletal treatments in Switzerland, including Alkindi, Miglustat Dipharma, Binosto, Dibase, Testavan, Lysodren, and Metopiron.
Go-to-market motion2 records
Distribution channels6 records
Marketing channels4 records
EffRx Pharmaceuticals product offering
Product offeringCore offering
EffRx Pharmaceuticals commercializes a portfolio of niche and orphan prescription medicines focused on rare endocrine, metabolic, and musculoskeletal disorders. Its lead proprietary product is Binosto, a buffered soluble effervescent alendronate tablet for osteoporosis, complemented by in-licensed rare disease products (Alkindi for pediatric adrenal insufficiency, Efmody for congenital adrenal hyperplasia, Miglustat Dipharma for Gaucher disease and Niemann-Pick type C) and additional Swiss-marketed products (Dibase, Testavan, Lysodren, Metopiron). The company directly sells its portfolio in Switzerland and out-licenses Binosto to regional commercialization partners across multiple continents.
Product overview
EffRx Pharmaceuticals is a commercial-stage pharmaceutical company that markets a portfolio of prescription medications for rare endocrine, metabolic and musculoskeletal disorders. The company's product portfolio includes proprietary products (Binosto®) and in-licensed rare disease therapies (Alkindi®, Efmody®, Miglustat Dipharma®), along with additional musculoskeletal and rare disease products (Dibase®, Testavan®, Lysodren®, Metopiron®) marketed directly in Switzerland. EffRx focuses on late-stage development and commercialization, with Binosto® as the lead commercialized product for osteoporosis, distributed globally through licensing partnerships across Europe, US, Asia and Middle East.
Differentiator
Problem solved
Functional benefit
Products and services
- Binosto® Binosto® (buffered soluble alendronate 70 mg) is an effervescent tablet for oral solution indicated for the treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. It is the first and only buffered solution for osteoporosis treatment, formulated to dissolve in water yielding a buffered oral solution (pH 4.8–5.4) that facilitates delivery to the stomach and reduces the potential for local and esophageal irritation compared with conventional alendronate tablets. Distributed globally through regional licensing partners.
- Alkindi® Alkindi® is an immediate-release hydrocortisone preparation specifically designed for pediatric patients with adrenal insufficiency. Available in color-coded capsules with four different dose strengths (0.5 mg, 1 mg, 2 mg, 5 mg), it enables individualized, accurate, and flexible dosing without the need for magisterial formulations or tablet fragmentation.
- Efmody® Efmody® is a modified-release preparation of hydrocortisone specifically designed for the treatment of patients with congenital adrenal hyperplasia (CAH). It mimics the body's natural cortisol circadian rhythm when given in a twice-a-day 'toothbrush' regimen.
- Miglustat Dipharma® Miglustat Dipharma® is an inhibitor of glucosylceramide synthase indicated for oral treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable, and for treatment of progressive neurological manifestations in adult and pediatric patients with Niemann-Pick type C disease.
- Dibase® Dibase® is a vitamin D supplement marketed in Switzerland, available in 10,000 IU and 25,000 IU formulations for the treatment of vitamin D deficiency.
- Testavan® Testavan® is a testosterone replacement therapy product marketed in Switzerland for the treatment of testosterone deficiency.
- Lysodren® Lysodren® is a product for the treatment of adrenocortical carcinoma (ACC), marketed in Switzerland by EffRx.
- Metopiron® Metopiron® is a product for the treatment of Cushing Syndrome, marketed in Switzerland by EffRx.
Quantifiable outcome
- Binosto demonstrated greater persistence compared to alendronate tablets in postmenopausal women with osteoporosis
- +2 more outcomes
Companies that use EffRx Pharmaceuticals
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
EffRx Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
EffRx Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- Compai PharmacoreExclusive licensing and distribution agreement for Binosto in Malaysia. Compai Pharma is a leading medical distribution company with strong reach across South East Asia. The partnership addresses underdiagnosis and undertreatment of osteoporosis in Malaysia.
- Pyridam Farma (PT Pyridam Farma Tbk)coreExclusive license and distribution agreement for Binosto in Indonesia. Pyridam Farma is a leading public listed pharmaceutical company in Indonesia. The partnership aims to enhance healthcare access for osteoporosis patients and deliver innovative solutions to the Indonesian healthcare system.
- Lupin LimitedcoreExclusive licensing and distribution agreement for Binosto in Vietnam and Philippines. Lupin, a leading global pharmaceutical company, will commercialize Binosto for postmenopausal osteoporosis treatment. EffRx will supply product to Lupin.
- Radius HealthcoreExclusive licensing and distribution agreement for Binosto in the United States. Radius Health, a major player in the U.S. bone market with TYMLOS, gained rights to commercialize Binosto for treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. EffRx will supply product to Radius.
- World Orphan Drug Alliance (WODA)coreWODA is a global alliance of regional full-service distributors for orphan drugs founded by EffRx together with Medis, Orpharm, Vector Pharma, and OrphanDC. The alliance covers 68 countries across Central/Eastern Europe, Latin America, Middle East/North Africa/Turkey, Russia/CIS, and Switzerland. WODA provides access to 64 million potential rare disease patients and offers full-service solutions including deep understanding of local healthcare systems and flexible partnership approaches.
- Diurnal Group plccoreExclusive license agreement for registration and commercialization of Efmody (modified-release hydrocortisone) for congenital adrenal hyperplasia (CAH) in Switzerland. EffRx received exclusive rights to register and commercialize Efmody in Switzerland, with plans to submit MAA to Swissmedic for adolescent and adult patients (12 years and older).
- Dipharma SAcoreExclusive license agreement for commercialization of Miglustat Dipharma in Switzerland. Miglustat Dipharma is a generic equivalent to Actelion's Zavesca for treatment of mild to moderate type 1 Gaucher disease and progressive neurological manifestations in Niemann-Pick type C disease. Product reimbursed in Switzerland as of November 2020.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
EffRx Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Radius Health: US specialty pharma commercializing TYMLOS for postmenopausal osteoporosis. Radius is EffRx's exclusive US licensing and distribution partner for Binosto, putting the two companies in allied/complementary positions in the same osteoporosis market while Radius also serves as EffRx's go-to channel for US growth.
- Cumberland Pharmaceuticals: US-based specialty pharma commercializing niche prescription products for underserved indications (including metabolic and endocrine). Comparable business model of focused, small-team commercialization of specialty molecules through selective physician targets.
- Diurnal Group plc: UK-based specialty pharma focused on cortisol-related endocrine disorders (CAH, adrenal insufficiency). Diurnal both partners with EffRx (licenses Efmody to EffRx for Switzerland) and competes with EffRx's Alkindi in overlapping pediatric/adult hydrocortisone markets, making it the closest direct peer.
- Amryt Pharma (Chiesi): Specialty rare-disease pharma with EU/US commercial platform focused on metabolic, endocrine, and rare dermatology indications. Was acquired by Chiesi in 2023; serves a comparable target prescriber base of rare disease specialists as EffRx.
- HRA Pharma: Mid-sized European specialty pharma focused on rare endocrine disorders (especially adrenal insufficiency, Cushing's, CAH) and underserved therapeutic niches. Head-to-head competitor for similar prescribers in Switzerland and continental Europe.
- Orphan Europe (Recordati Group): European-focused orphan drug distributor commercializing treatments for rare endocrine, metabolic, and lysosomal storage disorders via in-licensing. Closely mirrors EffRx's model of bringing orphan drugs to European patients with unmet needs.
Broad incumbents
- Recordati Rare Diseases: Specialty division of Recordati Group focused on rare diseases with broad European commercial platform and marketed endocrine/metabolic products. Comparable business model of in-licensing rare disease products and distributing across Europe through field sales.
- Sobi (Swedish Orphan Biovitrum): Large European rare-disease specialty pharma with established commercial footprint in endocrine and metabolic rare diseases (e.g., Kineret, Somavert). Operates broadly in the same orphan-drug commercialization model that EffRx uses in Switzerland, but at far larger scale and product breadth.
- Kyowa Kirin International: Specialty pharma with established European presence in rare endocrine and metabolic disorders (e.g., Crysvita, Poteligeo). Uses a niche in-licensing and orphan commercialization playbook comparable to EffRx's, but at much greater scale.
Emerging players
- Dipharma SA: Italian pharmaceutical company specializing in generic and rare disease products (Miglustat Dipharma originator). Licenses Miglustat Dipharma to EffRx for Switzerland and operates the same rare-disease/orphan commercial philosophy; partial overlap creates both partnership and competitor dynamics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights5 records
Customer concentration
EffRx Pharmaceuticals social profiles
Digital presenceEffRx Pharmaceuticals compliance and trust
Trust signalCompliance1 record
EffRx Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
EffRx Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles7 records
EffRx Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EffRx Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EffRx Pharmaceuticals
What does EffRx Pharmaceuticals do?
EffRx Pharmaceuticals commercializes a portfolio of niche and orphan prescription medicines focused on rare endocrine, metabolic, and musculoskeletal disorders. Its lead proprietary product is Binosto, a buffered soluble effervescent alendronate tablet for osteoporosis, complemented by in-licensed rare disease products (Alkindi for pediatric adrenal insufficiency, Efmody for congenital adrenal hyperplasia, Miglustat Dipharma for Gaucher disease and Niemann-Pick type C) and additional Swiss-marketed products (Dibase, Testavan, Lysodren, Metopiron). The company directly sells its portfolio in Switzerland and out-licenses Binosto to regional commercialization partners across multiple continents.
Is EffRx Pharmaceuticals a public or private company?
EffRx Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.
When was EffRx Pharmaceuticals founded?
EffRx Pharmaceuticals was founded in 1998. It employs 11 to 50 people.
Where is EffRx Pharmaceuticals based?
EffRx Pharmaceuticals is headquartered in Freienbach, Switzerland, in the Europe region.
How does EffRx Pharmaceuticals make money?
Two revenue lines are on record. Product Licensing and Royalty Revenue is the primary driver. The others are direct Product Sales in Switzerland.
Who are EffRx Pharmaceuticals's main competitors?
Direct peers on record are Radius Health, Cumberland Pharmaceuticals, Diurnal Group plc, Amryt Pharma (Chiesi), HRA Pharma and Orphan Europe (Recordati Group). Broad incumbents are Recordati Rare Diseases, Sobi (Swedish Orphan Biovitrum) and Kyowa Kirin International. Dipharma SA is listed as an emerging player.
Does EffRx Pharmaceuticals have an API?
No public API is recorded for EffRx Pharmaceuticals.
What industry is EffRx Pharmaceuticals in?
EffRx Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.